Pharmacokinetics and Pharmacodynamics of Gamma-hydroxybutyric Acid During Tolerance in Rats: Effects on Extracellular Dopamine.
From: Department of Pharmaceutical Sciences, H517 Cooke-Hochstetter, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260, USA.
The Journal of pharmacology and experimental therapeutics
- Publish Date: Mar 2007
- ISSN: 0022-3565
- Volume: 320
- Issue: 3
- Pages: 1252-60
- Medium: Print
- Language: English
- Citation (JAMA): Raybon Joseph J, Boje Kathleen M K, et al. Pharmacokinetics and Pharmacodynamics of Gamma-hydroxybutyric Acid During Tolerance in Rats: Effects on Extracellular Dopamine.. J. Pharmacol. Exp. Ther. Mar 2007;320:1252-60
Abstract
gamma-Hydroxybutyrate (GHB) is a potent sedative/hypnotic and drug of abuse. Tolerance develops to GHB’s sedative/hypnotic effects. It is hypothesized that GHB tolerance may be mediated by alterations in central nervous system pharmacokinetics or neurotransmitter response. Rats were dosed daily with GHB (548 mg/kg s.c. q.d. for 5 days), and sleep time was measured as an index of behavioral tolerance. Plasma and brain GHB pharmacokinetics on days 1 and 5 were monitored using blood and microdialysis sampling. Extracellular (ECF) striatal dopamine levels were measured by microdialysis as a pharmacodynamic endpoint of tolerance. Pharmacokinetic (PK)/pharmacodynamic (PD) modeling was performed to describe the plasma and brain disposition using an indirect response model with inhibition of dopamine synthesis rate to describe the pharmacodynamic response. GHB plasma and brain ECF concentration versus time profiles following acute or chronic exposure were not significantly different. GHB sedative/hypnotic tolerance was observed by day 5. Acute GHB administration resulted in a decrease in striatal ECF dopamine (DA) levels compared with baseline levels. GHB tolerance was reflected by a 60% decrease in dopamine area under the curve (effect and baseline): acute, 10.1 +/- 15.3% basal DA/min/10(-3) versus chronic, 4.73 +/- 1.49% basal DA/min/10(-3) (p < 0.05, n = 5; unpaired Student’s t test). The PK/PD model revealed an increase in the IC50 following chronic exposure indicating decreased dopaminergic sensitivity toward the inhibitory effects of GHB. Our findings indicate that GHB pharmacokinetics do not contribute to behavioral tolerance; however, changes in neurotransmitter responsiveness may suggest specific neurochemical pathways involved in the development and expression of tolerance.
Mesh Headings (Keywords): Animals, Brain, Dopamine, Drug Tolerance, Extracellular Fluid, Hydroxybutyrates, Hypnotics and Sedatives, Male, Microdialysis, Models, Biological, Rats, Rats, Sprague-Dawley, Sleep, Time Factors
Check for Full Text / PubMed Unique Identifier (PMID): 17138862
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.